Although first- and second-generation EGFR-TKIs (including gefitinib, erlotinib and afatinib) produce marked tumor response and improved progression-free survival (PFS) in NSCLC patient harboring activating EGFR mutation [4, 43], patients with wild-type EGFR and KRAS mutation are not sensitive to these EGFR-TKIs [5, 9, 43]. Here, KRAS is linked to neoplasm.